GI-102 + Pasritamig for Prostate Cancer

This trial tests a new treatment combination for men with prostate cancer that has spread and isn't responding to standard hormone therapies. The goal is to determine if the drugs GI-102 (an experimental treatment) and pasritamig are safe and effective against cancer. The trial includes different groups to assess the optimal frequency of treatment administration. Men with prostate cancer that hasn't improved with previous hormone treatments and who have noticeable disease symptoms might be suitable candidates. As a Phase 1 and Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to be among the first to benefit from a potentially groundbreaking therapy.

Research has shown that GI-102 has been tested in cancer patients, with fever and chills as the most common side effects, affecting about 44% of patients. Other studies have examined GI-102 for its safety and potential to help the immune system fight cancer.

Specific safety information for pasritamig is not yet available. However, this trial is in an early stage, so researchers are closely monitoring safety and side effects.

Researchers are excited about the combination of GI-102 and pasritamig for prostate cancer treatment because it offers a novel approach by targeting the immune system. Unlike traditional hormone therapies or chemotherapy, GI-102 is a fusion protein combining CD80 and IL2, which may enhance the body's immune response against cancer cells. Additionally, pasritamig’s role as a potential immune modulator could complement GI-102, possibly leading to more effective tumor suppression. This unique mechanism of action sets it apart from current treatments and holds promise for improved outcomes in managing prostate cancer.

Research shows that GI-102 helps the immune system fight cancer. Early studies have found it active in prostate cancer patients, suggesting potential effectiveness for other cancer types. Pasritamig, another treatment, has shown promising results against tumors, especially when combined with docetaxel in advanced prostate cancer. Past studies demonstrated that pasritamig significantly lowered prostate-specific antigen (PSA) levels, indicating it might slow cancer growth. This trial tests these treatments together in various dosing schedules to determine if they can better manage prostate cancer that has spread and hasn't responded to other treatments.⁶⁷⁸⁹¹⁰